Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a targeted oncology panel at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 12:50 p.m. ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About Immunome, Inc.

Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including radioligand therapies, ADCs, small molecules, and immunotherapies. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets.

For more information, visit www.immunome.com or follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240301342590/en/

The Immunome Stock at the time of publication of the news with a fall of -1,06 % to 24,20USD on Nasdaq stock exchange (01. März 2024, 02:00 Uhr).